Ozempic vs Wegovy: What's the Difference?
Reviewed by Sydney Duong, RD, GLPeak Clinical Lead · Last updated 2026-06-17
Quick answer: Ozempic and Wegovy are the same drug — semaglutide, made by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes and tops out at 2.0 mg weekly. Wegovy is FDA-approved for chronic weight management and goes up to 2.4 mg weekly. The molecule, injection device, and side-effect profile are otherwise identical.
Same drug, different label
Both medications contain semaglutide, a GLP-1 receptor agonist. The molecule is bioequivalent. What separates them is the FDA-approved indication and the maximum dose strength shipped in the pen.
Ozempic (approved 2017) is labeled for adults with type 2 diabetes. Wegovy (approved 2021) is labeled for chronic weight management in adults with a BMI ≥30, or ≥27 with a weight-related condition.
Dose and titration schedule
Both titrate up over months to reduce nausea and other GI side effects. The starting dose, schedule, and ceiling differ.
- Ozempic: 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg (ceiling). 4 weeks per step.
- Wegovy: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (ceiling). 4 weeks per step.
- Wegovy's higher max dose is the main driver of greater average weight loss in trials.
Weight-loss outcomes
In the STEP 1 trial, Wegovy 2.4 mg produced average weight loss of ~14.9% over 68 weeks vs ~2.4% on placebo. Ozempic 1.0 mg in the SUSTAIN trials produced average weight loss of ~6%. Real-world results vary widely with diet, activity, and adherence.
Cost and coverage
Ozempic is typically covered when prescribed for diabetes. Wegovy coverage for obesity is improving but still inconsistent — Medicare's GLP-1 Bridge program now provides some access at ~$50/month for eligible patients. Out-of-pocket list price for either pen is ~$1,000–$1,350/month before manufacturer savings cards.
Which should you ask about?
If you have type 2 diabetes, Ozempic is the on-label choice and almost always cheaper through insurance. If your goal is weight loss without diabetes, Wegovy is on-label and reaches the higher dose tier that drives the largest weight loss in trials. Your prescriber will choose based on your diagnosis, insurance formulary, and tolerability.
Frequently asked questions
Is Ozempic the same as Wegovy?
Both contain semaglutide and are made by Novo Nordisk. They are pharmacologically the same drug but have different FDA indications and maximum doses. Ozempic is labeled for type 2 diabetes (max 2.0 mg weekly); Wegovy is labeled for chronic weight management (max 2.4 mg weekly).
Can I switch from Ozempic to Wegovy?
Many patients do, with their prescriber's guidance. Typical practice is to continue at the same milligram dose (e.g. 1.0 mg Ozempic → 1.0 mg Wegovy) and then titrate up to Wegovy's 2.4 mg ceiling if tolerated. Insurance approval for Wegovy usually requires meeting BMI criteria.
Will I lose more weight on Wegovy than Ozempic?
On average yes, because Wegovy reaches a higher maximum dose (2.4 mg vs 2.0 mg) and that higher dose produces greater appetite suppression. STEP 1 trial participants on Wegovy lost ~14.9% of body weight; Ozempic patients in SUSTAIN trials at 1.0 mg lost ~6%. Individual results vary.
Do they have different side effects?
Side-effect profiles are essentially identical because the drug is the same: nausea, constipation or diarrhea, reflux, fatigue, and injection-site reactions. Wegovy's higher maximum dose can produce more pronounced GI symptoms in some patients.
References
Related GLPeak tools
Educational only — not medical advice. Consult your prescriber before changing any medication.